Frier Levitt attorney Steven L. Bennet was recently quoted in a MedCity News article, “House Decision on Drug Price Negotiations May Have Little Impact on Drug Industry” by Amanda James.
While there has been widespread praise for the start of Medicare negotiating drug prices in 2026 under the Inflation Reduction Act, not all believe it will have much of an impact on the drug industry. The Act fails to address patients who are covered by private insurance, as well as pharmacy benefit managers (“PBMs”) which negotiate drug prices.
“Generally, when drug prices are high or are increasing, industry players that profit from high drug prices financially benefit. Efforts to slow the growth of drug prices or decrease drug prices will have an impact on many of these industry players,” Bennet said. However, he concluded that, “The true impact of the relationship between industry players is very complex and the Senate bill may have a de minimis impact on large portions of the industry.”
Read the full article here.